BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 18720187)

  • 1. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
    Prodanovic EM; Korman NJ
    J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.
    Heizmann M; Itin P; Wernli M; Borradori L; Bargetzi MJ
    Am J Hematol; 2001 Feb; 66(2):142-4. PubMed ID: 11421295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.
    Barnadas M; Roe E; Brunet S; Garcia P; Bergua P; Pimentel L; Puig L; Francia A; García R; Gelpí C; Sierra J; Coll P; Alomar A
    J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):69-74. PubMed ID: 16405612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
    Arin MJ; Hunzelmann N
    Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment.
    Connelly EA; Aber C; Kleiner G; Nousari C; Charles C; Schachner LA
    Pediatr Dermatol; 2007; 24(2):172-6. PubMed ID: 17461818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities.
    Rossum MM; Verhaegen NT; Jonkman MF; Mackenzie MA; Koster A; Van Der Valk PG; Span LF
    Leuk Lymphoma; 2004 Nov; 45(11):2327-32. PubMed ID: 15512825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.
    Schadlow MB; Anhalt GJ; Sinha AA
    J Drugs Dermatol; 2003 Oct; 2(5):564-7. PubMed ID: 14558407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
    Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
    Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
    Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
    Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia.
    Taintor AR; Leiferman KM; Hashimoto T; Ishii N; Zone JJ; Hull CM
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S73-6. PubMed ID: 17434044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
    Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
    Schmidt HH; Renner H; Linkesch W
    Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy.
    Hoque SR; Black MM; Cliff S
    Clin Exp Dermatol; 2007 Mar; 32(2):172-5. PubMed ID: 17342796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of follicular lymphoma complicated with lethal pemphigus].
    Imataki O; Tamai Y; Abe Y; Ito I; Yoshikawa S; Kawakami K
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1677-80. PubMed ID: 17108741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed response of oral pemphigus vulgaris to rituximab treatment.
    Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
    Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.